Upgrade for detailed insurance, legislation, and other documents analytics for individual cases; real-time analysis of the datasets from your EHR, CRM, ERP, or other software; and more Enterprise Features.
ALL MEDICAL CODES IN CATEGORY Medicare Demonstration Projects
2025 HCPCS code G9073
Invasive female breast cancer, predominantly adenocarcinoma, Stage IIIA-IIIB (not T3, N1, M0), ER/PR positive, no progression/recurrence/metastasis, not ductal carcinoma in situ.
2025 HCPCS code G9085
Reports information on a patient's colon cancer disease status within a specific Medicare demonstration project.
2025 HCPCS code G9066
Reports information on a patient's disease status for non-small cell lung cancer (NSCLC), specifically stages IIIB-IV at diagnosis (metastatic, locally recurrent, or progressive), used within a Medicare demonstration project.
2025 HCPCS code G9106
Provides information on the disease status of pancreatic cancer (adenocarcinoma) post-R1 or R2 resection, with no disease progression or metastases; used in a Medicare-approved demonstration project.
2025 HCPCS code G9108
Provides information on the disease status of metastatic pancreatic adenocarcinoma with unknown extent of progression; used in a 2006 Medicare demonstration project.
2025 HCPCS code G9116
This HCPCS code reports information on the disease status of ovarian epithelial cancer (progressive, recurrent, or platinum-resistant) as part of a 2006 Medicare demonstration project.
2025 HCPCS code G9139
Provides information about chronic myelogenous leukemia (CML) positive for the Philadelphia chromosome or BCR-ABL gene, used in a 2006 Medicare demonstration project.
2025 HCPCS code G9123
This HCPCS code reports chronic myelogenous leukemia (CML) status, positive for the Philadelphia chromosome or BCR-ABL gene, in the chronic phase and not in remission.
2025 HCPCS code G9114
This HCPCS code reports the disease status of ovarian cancer (epithelial, stages IA-B, or IC), specifically within the context of a past Medicare demonstration project (2006).
2025 HCPCS code G9124
This HCPCS code reports information about chronic myelogenous leukemia (CML) positive for the Philadelphia chromosome or BCR-ABL gene, in the accelerated phase and not in remission.
2025 HCPCS code G9056
This HCPCS code reports adherence to practice guidelines for oncology treatment within a specific Medicare demonstration project.
2025 HCPCS code G9117
This HCPCS code reports the disease status of ovarian cancer, specifically epithelial cancer with unknown progression extent, for a Medicare demonstration project (2006).
2025 HCPCS code G9138
Provides information on the disease status of non-Hodgkin's lymphoma undergoing evaluation for response to therapy or recurrence, with the current stage unverified.Used as part of a 2006 Medicare demonstration project.
2025 HCPCS code G9090
Reports the disease status of a patient's rectal cancer, specifically limited invasive adenocarcinoma (T1-2, N0, M0) before neoadjuvant therapy, within a Medicare demonstration project.
2025 HCPCS code G9013
This HCPCS code reports an end-stage renal disease (ESRD) demonstration project basic bundle level one service.
2025 HCPCS code G9099
This HCPCS code reports information on the disease status of esophageal cancer (adenocarcinoma or squamous cell carcinoma), including staging, for a specific Medicare demonstration project in 2006.
2025 HCPCS code G9109
头颈部癌的疾病状态，仅限于以鳞状细胞为主要细胞类型的口腔癌、咽癌和喉癌，未显示疾病进展。
2025 HCPCS code G9107
肿瘤学-其他
2025 HCPCS code G9084
Oncología: otra. Estado actual de la oncología: cáncer de colon, limitado a invasivo, con predominio del adenocarcinoma, T1-T3, N0, M0, no hay evidencia de progresión, recurrencia o metástasis.
2025 HCPCS code G9107
Oncology - other
2025 HCPCS code G9068
Oncology disease status limited to small cell and combined small cell/non-small cell; extent of disease initially established as limited with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project).
2025 HCPCS code G9134
Non-Hodgkin’s lymphoma, stage I/II, any cell type, not relapsed/recurrent, nonrefractory.
2025 HCPCS code G9128
Multiple Myeloma, Stage IA
2025 HCPCS code G9079
Oncology - Prostate cancer, limited to adenocarcinoma, T3B to T4, any N, any T, at initial diagnosis was N1, no evidence of disease progression, recurrence, or metastasis, for Medicare demonstration project.
2025 HCPCS code G9070
Reports information on a patient's small cell lung cancer disease status (extent unknown, staging in progress, or not listed) for a Medicare demonstration project.
2025 HCPCS code G9112
This HCPCS code reports information on head and neck cancer status, including staging, for a specific Medicare demonstration project in 2006.
2025 HCPCS code G9083
Reports the disease status of a patient's prostate cancer, limited to adenocarcinoma, where the extent of the disease is unknown, staging is in progress, or not listed in the record; used in a Medicare-approved demonstration project.
2025 HCPCS code G9075
Reports information on the disease status of a patient's invasive female breast cancer (adenocarcinoma, M1 stage at diagnosis, metastatic, locally recurrent, or progressive; excludes ductal carcinoma origin).
2025 HCPCS code G9050
This HCPCS code reports the primary focus of an evaluation and management (E/M) visit for a cancer patient, including work-up, evaluation, or staging at diagnosis or recurrence.
2025 HCPCS code G9077
Reports information on prostate cancer disease status for a Medicare-approved demonstration project.
2025 HCPCS code G9058
Reports that patient management differs from practice guidelines due to provider disagreement with recommendations; used in a Medicare demonstration project.
2025 HCPCS code G9078
Reports disease status of prostate cancer (limited to adenocarcinoma, T2 or T3a, Gleason 8-10, or PSA >20 at diagnosis) within a Medicare-approved demonstration project.
2025 HCPCS code G9096
Reports information on the disease status of a patient's esophageal cancer, specifically adenocarcinoma or squamous cell carcinoma, staged T1-T3, N0-N1 or NX, before neoadjuvant therapy, with no evidence of progression, recurrence, or metastasis (Medicare demonstration project).
2025 HCPCS code G9088
Oncology - other
2025 HCPCS code G9080
Oncology - Other
2025 HCPCS code G9084
Oncology - other. Current Disease Status of Oncology, Colon Cancer, Limited to Invasive, Adenocarcinoma Predominant, T1-T3, N0, M0, No Evidence of Progression, Recurrence or Metastases.
2025 HCPCS code G9072
Oncology - other
2025 HCPCS code G9132
Oncology - Other
2025 HCPCS code G9104
Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed.
2025 HCPCS code G9136
Disease status of non-Hodgkin’s lymphoma with transformation of cell type from one classification to another (Used in a Medicare demonstration project in 2006).
2025 HCPCS code G9093
Rectal cancer, limited to invasive, predominantly adenocarcinoma, initial extent of disease T4, any N, M0, before neoadjuvant therapy, no evidence of progression, recurrence, or metastases.
2025 HCPCS code G9102
Oncology; disease status; gastric cancer, limited to adenocarcinoma, clinical or pathologic M0, unresectable with no evidence of disease progression (for use in a Medicare-approved demonstration project).
2025 HCPCS code G9126
Chronic Myelogenous Leukemia, positive for Philadelphia chromosome or BCR/ABL gene, in remission.
2025 HCPCS code G9061
Available practice guidelines do not address the patient's specific cancer condition.
2025 HCPCS code G9109
Disease status of head and neck cancer, limited to cancers of the oral cavity, pharynx, and larynx with squamous cell as the predominant cell type, showing no disease progression.
2025 HCPCS code G9069
Oncology - disease status; small cell lung cancer (limited to small cell and combined small cell/non-small cell); extensive stage at diagnosis, metastatic, locally recurrent, or progressive. For use in a Medicare-approved demonstration project.
2025 HCPCS code G9094
Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project).
2025 HCPCS code G9060
Oncology - Management Differs From Practice Guidelines.
2025 HCPCS code G9016
Smoking cessation counseling, individual, per session (6-10 minutes), used in Medicare demonstration projects.
2025 HCPCS code G9092
Oncology - Rectal Cancer, Limited to Invasive, Predominantly Adenocarcinoma, T1-T3, N1-N2, M0, Pre-Neoadjuvant Therapy, No Evidence of Progression/Recurrence/Metastases
Continue with Personal Account
Thank you for exploring iFrame ♥ Please subscribe for unlimited access to our top-tier AI model, which directly supports our dedicated knowledge creators maintaining an ad-free internet experience.